Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:GMAB NASDAQ:KRYS NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$208.71+0.1%$197.95$118.03▼$216.45$12.86B0.41455,965 shs231,201 shsGMABGenmab A/S$32.75+0.2%$27.29$17.24▼$33.63$20.98B0.982.40 million shs3.03 million shsKRYSKrystal Biotech$188.05+1.8%$157.48$122.80▼$207.84$5.35B0.64344,538 shs224,260 shsSMMTSummit Therapeutics$21.75-5.1%$22.87$15.55▼$36.91$17.03B-1.133.90 million shs2.24 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.13%-0.55%+6.71%+18.99%+62.47%GMABGenmab A/S+0.21%+0.34%+17.72%+49.75%+38.42%KRYSKrystal Biotech+1.79%+2.75%+30.88%+25.30%+4.72%SMMTSummit Therapeutics-5.15%-2.42%+14.84%-23.06%+7.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$208.71+0.1%$197.95$118.03▼$216.45$12.86B0.41455,965 shs231,201 shsGMABGenmab A/S$32.75+0.2%$27.29$17.24▼$33.63$20.98B0.982.40 million shs3.03 million shsKRYSKrystal Biotech$188.05+1.8%$157.48$122.80▼$207.84$5.35B0.64344,538 shs224,260 shsSMMTSummit Therapeutics$21.75-5.1%$22.87$15.55▼$36.91$17.03B-1.133.90 million shs2.24 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.13%-0.55%+6.71%+18.99%+62.47%GMABGenmab A/S+0.21%+0.34%+17.72%+49.75%+38.42%KRYSKrystal Biotech+1.79%+2.75%+30.88%+25.30%+4.72%SMMTSummit Therapeutics-5.15%-2.42%+14.84%-23.06%+7.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.88Moderate Buy$248.2918.96% UpsideGMABGenmab A/S 2.82Moderate Buy$40.8024.58% UpsideKRYSKrystal Biotech 2.75Moderate Buy$209.0011.14% UpsideSMMTSummit Therapeutics 2.44Hold$31.2943.84% UpsideCurrent Analyst Ratings BreakdownLatest KRYS, GMAB, SMMT, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.0010/8/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GMABGenmab A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025SMMTSummit TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025GMABGenmab A/SZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/2/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $40.009/27/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GMABGenmab A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M32.72N/AN/A($1.88) per share-111.02GMABGenmab A/S$3.12B6.73$1.52 per share21.55$8.04 per share4.07KRYSKrystal Biotech$290.52M18.73$4.72 per share39.84$32.90 per share5.72SMMTSummit Therapeutics$700K23,081.41N/AN/A$0.53 per share41.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A869.63N/A-54.94%N/A-24.31%11/13/2025 (Estimated)GMABGenmab A/S$1.14B$1.9916.4618.401.8437.53%21.03%16.98%11/6/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9238.2218.66N/A40.85%15.21%13.81%11/3/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest KRYS, GMAB, SMMT, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GMABGenmab A/S$0.47N/AN/AN/A$975.40 millionN/A11/3/2025Q3 2025KRYSKrystal Biotech$1.04N/AN/AN/A$93.72 millionN/A10/29/2025Q3 2025SMMTSummit Therapeutics-$0.15N/AN/AN/AN/AN/A8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69GMABGenmab A/SN/A6.226.20KRYSKrystal BiotechN/A9.689.33SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AGMABGenmab A/S7.07%KRYSKrystal Biotech86.29%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%GMABGenmab A/S1.54%KRYSKrystal Biotech13.70%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableGMABGenmab A/S2,682642.06 million632.18 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableKRYS, GMAB, SMMT, and ASND HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.9% - Time to Sell?October 14 at 3:21 PM | marketbeat.comSummit Therapeutics PLC $SMMT Shares Sold by Aberdeen Group plcOctober 14 at 4:03 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 13 at 2:00 PM | prnewswire.comAPEIRON CAPITAL Ltd Takes $25.56 Million Position in Summit Therapeutics PLC $SMMTOctober 12 at 5:04 AM | marketbeat.comSummit Therapeutics' (SMMT) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 8, 2025 | prnewswire.comWhere is Summit Therapeutics (SMMT) Headed According to Analysts?October 8, 2025 | finance.yahoo.com14 Biotech Stocks with High PotentialOctober 7, 2025 | insidermonkey.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Hold" from BrokeragesOctober 7, 2025 | americanbankingnews.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Hold" by BrokeragesOctober 7, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMTOctober 6, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Summit Therapeutics (SMMT) and United Therapeutics (UTHR)October 5, 2025 | theglobeandmail.com1 Monster Stock in the Making to Buy and HoldOctober 5, 2025 | fool.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 3, 2025 | prnewswire.comA Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal InvestigationOctober 2, 2025 | finance.yahoo.comH.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab MilestonesOctober 2, 2025 | msn.comSummit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025October 1, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving Average - What's Next?October 1, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 28, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 24, 2025 | globenewswire.comHARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in ...September 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRYS, GMAB, SMMT, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$208.71 +0.28 (+0.13%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$204.74 -3.97 (-1.90%) As of 10/14/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Genmab A/S NASDAQ:GMAB$32.75 +0.07 (+0.21%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$32.88 +0.13 (+0.40%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Krystal Biotech NASDAQ:KRYS$188.05 +3.31 (+1.79%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$186.68 -1.37 (-0.73%) As of 10/14/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Summit Therapeutics NASDAQ:SMMT$21.75 -1.18 (-5.15%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$21.85 +0.10 (+0.48%) As of 10/14/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
